Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial

Overview of attention for article published in Journal of Clinical Oncology, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 4 news outlets
blogs: 2 blogs
twitter: 31 X users

guideline: 1 clinical guideline source
bluesky: 1 Bluesky user

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 32 X posts from 31 X users, with an upper bound of 119,048 followers.

Radium-223 addition to stereotactic ablative radiotherapy for bone metastatic prostate cancer showed no benefit in delaying disease progression. by Wang JH, Sherry AD (...) Kiess AP et 31 al. in J Clin Oncol https://t.co/Uhf9RT1DfO #MedX #MedResearch

Combining Radium-223 with SABR in bone metastatic prostate cancer fails to improve progression-free survival. by Wang JH, Sherry AD (...) Kiess AP et 31 al. in J Clin Oncol https://t.co/Uhf9RT1DfO #MedX #MedResearch

#ProstateCancer RAVENS Trial ▶️ No PFS benefit in the addition of Radium-223 to SART in mHSPC https://t.co/dDqsnuLF7g

RT @APCCC_Lugano: Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastat…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 28 additional X posts.